Freeman Chris sold $10.8M of GH

Freeman Chris (Chief Commercial Officer) sold 63,605 shares of Guardant Health, Inc. (GH) at an average of $169.58 ($167.38–$170.24, $10.79M total) across 4 trades on 2026-08-10.

Original reporting
SEC EDGAR · Freeman Chris
Published Aug 11, 2026, 10:22 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Aug 11, 2026, 10:23 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
AlphAI market briefInsider activity
Primary signal
$GH
Neutral
medium confidence
Mentioned
$GH
Relevance
7/10
AlphAI data visualization · based on SEC EDGAR
Decision brief

The 30-second read

$GHNeutralLow
01

Why it matters

A Chief Commercial Officer’s multi-tranche open-market sale totaling ~$10.79M can affect short-term sentiment, but it is not a corporate action or operating update.

02

Market read

Traders may monitor for subsequent insider activity or any company-specific catalysts, but this filing alone is unlikely to drive a durable repricing.

03

What to watch

The filing does not state a 10b5-1 plan, but it also does not provide the insider’s rationale; without follow-on buying or guidance changes, fundamental impact is uncertain.

Relevance 7/10Novelty 5/10Timing: filed Aug 11 after Aug 10 sale trades

Background

The article is a SEC Form 4 insider transaction disclosure for Guardant Health, Inc.

Company-level read

Ticker impact

$GHNeutralMedium confidence
Context

Guardant Health Form 4 shows CCO Freeman Chris sold 63,605 shares in open-market trades for about $10.79M at ~$169.58 average.

Expected impact

Near-term price impact is likely limited, but it can add short-term overhang or raise questions about insider conviction.

Evidence & confidence

Form 4 insider sales can be routine and do not confirm negative fundamentals; however, the size and absence of a stated 10b5-1 plan can influence sentiment and trading flows.

Market effects

No direct sector read-through beyond general sentiment around biotech/healthcare insider activity.

None indicated.

None indicated.

Counterpoint

The sale may be unrelated to company outlook (taxes, diversification, planned liquidity needs), so it should not be treated as a strong bearish signal.

Key entities

  • Guardant Health, Inc.

    Public company whose insider transaction is disclosed on Form 4.

  • Freeman Chris

    Chief Commercial Officer who sold 63,605 shares across four trades on Aug 10.

Full insider trading history

This story covers one filing. See everything behind it: every insider buy and sell on record, 10b5-1 plans, late filings, and which officers and directors are trading.

Related articles

$GHHighAI 8/10

Why is Guardant Health stock climbing today?

Guardant Health (GH) stock rose 2.5% in pre-market trading after pricing a $500M offering of 0% convertible notes due 2032, with a 35% premium conversion price. The company plans to use proceeds to repurchase $395.2M of existing convertible notes due 2027, optimizing its balance sheet. The move came amid broader market headwinds for growth and tech names.